Healthcare >> Analyst Interviews >> April 21, 2017
Gene Therapy Space Grows More Disruptive and Competitive
Edward Nash has been a Managing Director in SunTrust Robinson Humphrey’s Equity Research department since July 2014. He started his career on the buy side covering the biotech sector and has spent 17 years covering biotech as a senior sellside analyst. Mr. Nash focuses on thematic investment ideas that straddle all market caps. Prior to joining SunTrust Robinson Humphrey, he was a Managing Director and Senior Research Analyst at Cowen and Company in equity research. Mr. Nash holds an MPH degree in epidemiology from The University of Alabama at Birmingham. Mr. Nash earned both an MBA in finance and an M.S. in international business from the University of Miami. He graduated from Spring Hill College with a B.S. in biology and chemistry. Profile
TWST: Can you talk about briefly the areas of your coverage currently?
Mr. Nash: My focus areas are on the antibiotic, gene therapy, hepatobiliary, CNS and orphan